Antithrombotic strategies for the management of non-valvular atrial fibrillation

International Journal of Cardiology

Volumn 100, Issue 2, 2005, Pages 191-198

  Nixdorff, Uwe ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Atrial fibrillation; Cardioversion; Low molecular weight heparin; Oral anticoagulation; Transesophageal echocardiography

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PHENPROCOUMON; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; BRAIN EMBOLISM; CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG MONITORING; DRUG SAFETY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART CATHETERIZATION; HEART RATE; HEART VALVE; HEPARINIZATION; HUMAN; INCIDENCE; INJECTION SITE REACTION; LIVER DYSFUNCTION; LONG TERM CARE; META ANALYSIS; PATIENT MONITORING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PULMONARY VEIN OSTIAL ISOLATION; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; STROKE; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TOXICITY; TRANSIENT ISCHEMIC ATTACK; TREATMENT PLANNING;

EID: 17044364725     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.12.030     Document Type: Review

References (50)

1. R.H. Falk Atrial fibrillation N Engl J Med 344 2001 1067 1078
2. M.D. Ezekowitz, and P.I. Netrebko Anticoagulation management of atrial fibrillation Curr Opin Cardiol 18 2003 26 31
3. W.M. Feinberg, J.L. Blackshear, A. Laupacis, R. Kronmal, and R.G. Hart Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications Arch Intern Med 155 1995 469 473
4. A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, and J.V. Selby Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
5. J. Friberg, H. Scharling, N. Gadsbøll, T. Truelsen, and G.B. Jensen Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (the Copenhagen city heart study) Am J Cardiol 94 2004 889 894
6. S. Stewart, N. Murphy, A. Walker, A. McGuire, and J.J.V. McMurray Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK Heart 90 2004 286 292
7. K.M. Ryder, and E.J. Benjamin Epidemiology and significance of atrial fibrillation Am J Cardiol 84 1999 131R 138R
8. T.S. Tsang, G.W. Petty, M.E. Barnes, W.M. O'Fallon, K.R. Bailey, and D.O. Wiebers The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades J Am Coll Cardiol 42 2003 93 100
9. G.W. Albers, J.E. Dalen, A. Laupacis, W.J. Manning, P. Petersen, and D.E. Singer Antithrombotic therapy in atrial fibrillation Chest 119 2001 194S 206S
10. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
11. C.J. Bjerkelund, and OM. Orning The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation Am J Cardiol 23 1969 208 216
12. V. Fuster, L.E. Ryden, R.W. Asinger, D.S. Cannom, H.J. Crijns, and R.L. Fyre American college of cardiology/American heart association task force on practice guidelines; European society of cardiology committee for practice guidelines and policy conferences (Committee to develop guidelines for the management of patients with atrial fibrillation); North American society of pacing and electrophysiology Circulation 104 2001 2118 2150
13. D.G. Wyse, A.L. Waldo, J.P. DiMarco, M.J. Domanski, Y. Rosenberg, and E.B. Schron A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833
14. I.C. Van Gelder, V.E. Hagens, H.A. Bosker, J.H. Kingma, O. Kamp, and T. Kingma A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 2002 1834 1840
15. G.N. Kay, K.A. Ellenbogen, M. Giudici, M.M. Redfield, L.S. Jenkins, and M. Mianulli The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators J Interv Card Electrophysiol 2 1998 121 135
16. H. Pürerfellner, M. Martinek, J. Aichinger, H.J. Nesser, K. Kempen, and J.P.G. Janssen Quality of life restored to normal in patients with atrial fibrillation after pulmonary vein ostial isolation Am Heart J 148 2004 318 325
17. M. Lamassa, A. Di Carlo, G. Pracucci, A.M. Basile, G. Trefoloni, and P. Vanni Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project) Stroke 32 2001 392 398
18. G.Y. Lip Does atrial fibrillation confer a hypercoagulable state? Lancet 346 1995 1313 1314
19. D. Fatkin, D.L. Kuchar, C.W. Thorburn, and M.P. Feneley Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications J Am Coll Cardiol 23 1994 307 316
20. E.M. Hylek, A.S. Go, Y. Chang, N.G. Jensvold, L.E. Henault, and J.V. Selby Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019 1026
21. A.S. Go, E.M. Hylek, K.A. Phillips, L.H. Borowsky, L.E. Henault, and Y. Chang Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study Circulation 102 2000 11 13
22. R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 1999 492 501
23. A.H. Abdelhafiz A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation Clin Ther 23 2001 1628 1636
24. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients BMJ 324 2002 71 86
25. S. Kamath, A.D. Blann, B.S. Chin, and G.Y. Lip A prospective randomised trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation J Am Coll Cardiol 40 2002 484 490
26. R.G. Hart, B.S. Boop, and D.C. Anderson Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses Stroke 26 1995 1471 1477
27. J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 3 Suppl. 2004 204S 233S
28. T.J. Bungard, W.A. Ghali, K.K. Teo, F.A. McAlister, and R.T. Tsuyuki Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 160 2000 41 46
29. C.P. Gross, E.W. Vogel, A.J. Dhond, C.B. Marple, R.A. Edwards, and O. Hauch Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey Clin Ther 25 2003 1750 1764
30. M.H. Kim, F. Morady, B. Conlon, S. Kronick, M. Lowell, and D. Bruckman A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation strategy with low-molecular-weight heparin Ann Emerg Med 40 2002 187 192
31. M.H. Kim, B.F. Decena, D. Bruckman, and K.A. Eagle Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation Am Heart J 145 2003 665 669
32. A.L. Klein, R.A. Grimm, I.W. Black, D.Y. Leung, M.K. Chung, and S.E. Vaughn Cardioversion guided by transesophageal echocardiography: the ACUTE pilot study Ann Intern Med 126 1997 200 209
33. A.L. Klein, R.A. Grimm, R.D. Murray, C. Apperson-Hansen, R.W. Asinger, and I.W. Black Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N Engl J Med 344 2001 1411 1420
34. A.L. Klein, R.D. Murray, R.A. Grimm, J. Li, C. Apperson-Hansen, and S.E. Jasper Bleeding complications in patients with atrial fibrillation undergoing cardioversion randomized to transesophageal echocardiographically guided and conventional anticoagulation therapies Am J Cardiol 92 2003 161 165
35. M. Khazan, S. Scheuering, R. Adamson, and A.S. Mathis Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation Pharmacotherapy 23 2003 651 658
36. I.C. Van Gelder, H.J. Crijns, R.G. Tieleman, J. Brugemann, P.J. De Kam, and A.T. Gosselink Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation Arch Intern Med 156 1996 2585 2592
37. C. Stellbrink, U. Nixdorff, T. Hofmann, W. Lehmacher, W.G. Daniel, and P. Hanrath Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial Circulation 109 2004 997 1003
38. Z. Yigit, M.S. Kucukoglu, B. Okcun, V. Sansoy, and D. Guzelsoy The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation Jpn Heart J 44 2003 369 377
39. H. Bechtold, D. Gunzenhauser, H. Sawitzki, S. Fung, and D. Janssen Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion Z Kardiol 92 2003 532 539
40. R.D. Murray, A. Shah, S.E. Jasper, A. Goodman, S.R. Deitcher, and W.E. Katz Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study Am Heart J 139 2000 1 7
41. M. Sorino, P. Colonna, S. Carerj, E. Oliva, S.M. De Tommasi, and U. Conti Post cardioversion transeosophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients. The multicenter POSTEC trial: a pilot study Circulation 108 2003 IV-473 [Abstract 2168]
42. A.H. Tinmouth, B.H. Morrow, M.K. Cruickshank, P.M. Moore, and M.J. Kovacs Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis Ann Pharmacother 35 2001 669 674
43. J.M. Galla, and B.E. Fuhs Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac surgery J Am Coll Cardiol 35 2000 531A [Abstract 1114-64]
44. J. Johnson, and A.G.G. Turpie Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin Thromb Haemost 2001 2323 [Abstract]
45. M.J. Kovacs, C. Kearon, M. Rodger, D.R. Anderson, A.G. Turpie, and S.M. Bates Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin Circulation 110 2004 1658 1663
46. H. Omran, C. Hammerstingl, H. Schmidt, G. von der Recke, W.D. Paar, and B. Luderitz A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization Thromb Haemost 90 2003 267 271
47. P. Petersen, M. Grind, and J. Adler SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study J Am Coll Cardiol 41 2003 1445 1451
48. S.B. Olsson Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor; SPORTIF II Investigators fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
49. Halperin JL. SPORTIF III and V Study Investigators. Efficacy and safety of oral direct thrombin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V). AHA Plenary Session VII.
50. S.S. Shapiro Treating thrombosis in the 21st century N Engl J Med 349 2003 1762 1764